TISIDB

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00782 Dual specificity phosphatase PF00581 Rhodanese-like domain
Function	Dual specificity phosphatase that dephosphorylates MAP kinase MAPK1/ERK2 on both 'Thr-183' and 'Tyr-185', regulating its activity during the meiotic cell cycle.

> Gene Ontology [ TOP ]
Biological Process	GO:0000070 mitotic sister chromatid segregation GO:0000075 cell cycle checkpoint GO:0000188 inactivation of MAPK activity GO:0000302 response to reactive oxygen species GO:0000819 sister chromatid segregation GO:0001101 response to acid chemical GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0006470 protein dephosphorylation GO:0006979 response to oxidative stress GO:0007050 cell cycle arrest GO:0007059 chromosome segregation GO:0007067 mitotic nuclear division GO:0007088 regulation of mitotic nuclear division GO:0007091 metaphase/anaphase transition of mitotic cell cycle GO:0007093 mitotic cell cycle checkpoint GO:0007094 mitotic spindle assembly checkpoint GO:0007346 regulation of mitotic cell cycle GO:0007369 gastrulation GO:0007492 endoderm development GO:0009314 response to radiation GO:0009416 response to light stimulus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010639 negative regulation of organelle organization GO:0010948 negative regulation of cell cycle process GO:0010965 regulation of mitotic sister chromatid separation GO:0014074 response to purine-containing compound GO:0016311 dephosphorylation GO:0030071 regulation of mitotic metaphase/anaphase transition GO:0031577 spindle checkpoint GO:0031960 response to corticosteroid GO:0032355 response to estradiol GO:0032526 response to retinoic acid GO:0033044 regulation of chromosome organization GO:0033045 regulation of sister chromatid segregation GO:0033046 negative regulation of sister chromatid segregation GO:0033047 regulation of mitotic sister chromatid segregation GO:0033048 negative regulation of mitotic sister chromatid segregation GO:0033574 response to testosterone GO:0033673 negative regulation of kinase activity GO:0035335 peptidyl-tyrosine dephosphorylation GO:0035970 peptidyl-threonine dephosphorylation GO:0042326 negative regulation of phosphorylation GO:0042542 response to hydrogen peroxide GO:0043405 regulation of MAP kinase activity GO:0043407 negative regulation of MAP kinase activity GO:0043409 negative regulation of MAPK cascade GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044784 metaphase/anaphase transition of cell cycle GO:0045786 negative regulation of cell cycle GO:0045839 negative regulation of mitotic nuclear division GO:0045841 negative regulation of mitotic metaphase/anaphase transition GO:0045930 negative regulation of mitotic cell cycle GO:0046683 response to organophosphorus GO:0048545 response to steroid hormone GO:0051052 regulation of DNA metabolic process GO:0051053 negative regulation of DNA metabolic process GO:0051304 chromosome separation GO:0051306 mitotic sister chromatid separation GO:0051321 meiotic cell cycle GO:0051348 negative regulation of transferase activity GO:0051384 response to glucocorticoid GO:0051445 regulation of meiotic cell cycle GO:0051447 negative regulation of meiotic cell cycle GO:0051591 response to cAMP GO:0051592 response to calcium ion GO:0051783 regulation of nuclear division GO:0051784 negative regulation of nuclear division GO:0051983 regulation of chromosome segregation GO:0051985 negative regulation of chromosome segregation GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070373 negative regulation of ERK1 and ERK2 cascade GO:0071173 spindle assembly checkpoint GO:0071174 mitotic spindle checkpoint GO:0071850 mitotic cell cycle arrest GO:0071897 DNA biosynthetic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071901 negative regulation of protein serine/threonine kinase activity GO:0090231 regulation of spindle checkpoint GO:0090266 regulation of mitotic cell cycle spindle assembly checkpoint GO:0098813 nuclear chromosome segregation GO:1901654 response to ketone GO:1901976 regulation of cell cycle checkpoint GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902099 regulation of metaphase/anaphase transition of cell cycle GO:1902100 negative regulation of metaphase/anaphase transition of cell cycle GO:1902532 negative regulation of intracellular signal transduction GO:1903504 regulation of mitotic spindle checkpoint GO:2000241 regulation of reproductive process GO:2000242 negative regulation of reproductive process GO:2000278 regulation of DNA biosynthetic process GO:2000279 negative regulation of DNA biosynthetic process GO:2000816 negative regulation of mitotic sister chromatid separation GO:2001251 negative regulation of chromosome organization
Molecular Function	GO:0004721 phosphoprotein phosphatase activity GO:0004725 protein tyrosine phosphatase activity GO:0004726 non-membrane spanning protein tyrosine phosphatase activity GO:0008138 protein tyrosine/serine/threonine phosphatase activity GO:0008330 protein tyrosine/threonine phosphatase activity GO:0016791 phosphatase activity GO:0017017 MAP kinase tyrosine/serine/threonine phosphatase activity GO:0019838 growth factor binding GO:0033549 MAP kinase phosphatase activity GO:0042578 phosphoric ester hydrolase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04726 Serotonergic synapse
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-5675221: Negative regulation of MAPK pathway R-HSA-169893: Prolonged ERK activation events R-HSA-112409: RAF-independent MAPK1/3 activation R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04726 Serotonergic synapse

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5675221: Negative regulation of MAPK pathway
R-HSA-169893: Prolonged ERK activation events
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DUSP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between DUSP1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23319273	Prostate Carcinoma	Inhibit immunity	Studies revealed that the levels of expression of genes responsible for T-cell proliferation (C-FOS, C-JUN and DUSP1) and cellular migration (RGS1) were greater in Tregs from mCRPC patients as compared to values observed in healthy donors.

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DUSP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DUSP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.277	0.597
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.618	0.808
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.03	0.987
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.419	0.638
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.458	0.87
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.357	0.927
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.174	0.724
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.064	0.963
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.367	0.8
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.232	0.904
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.318	0.633
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.476	0.0296

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DUSP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DUSP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DUSP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DUSP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DUSP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DUSP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DUSP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DUSP1
Name	dual specificity phosphatase 1
Aliases	HVH1; CL100; MKP-1; PTPN10; MKP1; CL 100; MAP kinase phosphatase 1; dual specificity protein phosphatase hVH ......
Chromosomal Location	5q35.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DUSP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DUSP1